lopinavir + ritonavir + ribavirin

This is a combination of three antiviral drugs—lopinavir, ritonavir, and ribavirin—used together as an investigational therapy for viral infections such as COVID-19 and MERS-CoV. Lopinavir and ritonavir are both protease inhibitors; ritonavir acts primarily to boost the plasma levels of lopinavir by inhibiting its metabolism via cytochrome P450 3A4. Ribavirin is a guanosine analog with broad-spectrum antiviral activity that inhibits viral RNA synthesis. The combination has been studied in clinical trials for its potential to reduce viral load, shorten duration of symptoms, and improve outcomes in patients with mild to moderate COVID-19 when compared to standard care or dual therapy[1][2][3][5]. This regimen does not have a unique brand name or code name.